China monoclonal antibodies market is estimated to grow at a CAGR of 9.2% during the forecast period. A significant rise in cancer incidences and increasing launches of biosimilars are some potential factors accelerating market growth. To increase access to potential oncology treatment, the Chinese authorities have been granted approvals of monoclonal antibodies. For instance, in January 2020, Bio-Thera Solutions, Ltd. declared that China National Medical Products Administration (NMPA) launched QLETLI, a biosimilar to Humira (adalimumab).
Get Free Sample link @ https://www.omrglobal.com/request-sample/china-monoclonal-antibodies-market
It is the first adalimumab biosimilar granted by the NMPA which is indicated to treat three autoimmune diseases, which include ankylosing spondylitis, plaque psoriasis, and rheumatoid arthritis. It is the company’s first biosimilar gained regulatory approval, and it is the second biosimilar which is approved in China by the NMPA. The company is developing multiple additional planned biosimilars, which include biosimilars to Avastin and to Actemra/RoActemra. These are both currently being assessed in global Phase III clinical trials. The company is also pursuing biosimilars to Stelara and Simponi.
A full report of China Monoclonal Antibodies Market available @ https://www.omrglobal.com/industry-reports/china-monoclonal-antibodies-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
China Monoclonal Antibodies Market by Source
- Murine
- Chimeric
- Human
- Humanized
China Monoclonal Antibodies Market by Application
- Cancer
- Infectious Diseases
- Auto-Immune Diseases
- Inflammatory Diseases
- Others
Company Profiles
- Amgen Inc.
- Anhui Anke Biotechnology (Group) Co., Ltd.
- AstraZeneca plc
- CStone Pharmaceuticals
- GenorBioPharma Co., Ltd.
- Harbour BioMed (HBM)
- Innovent Biologics, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Viva Biotech (Shanghai) Ltd.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
The Report Covers
- Comprehensive research methodology of the China monoclonal antibodies market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the China monoclonal antibodies market.
- Insights about market determinants which are stimulating the China monoclonal antibodies market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/china-monoclonal-antibodies-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
